 The purpose of this study is to evaluate the efficacy and safety of switching elderly participants with treatment-resistant depression TRD from a prior antidepressant treatment to which they have not responded to either intranasal esketamine plus a new oral antidepressant or switching to a new oral antidepressant plus intranasal placebo. 